大葉大學圖書館 |

Utilization of a model vaccination system to evaluate the immunostimulatory characteristics of LicKM, a novel carrier molecule.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Utilization of a model vaccination system to evaluate the immunostimulatory characteristics of LicKM, a novel carrier molecule.
Author:	Chabot, Ashley Lynn.
Description:	95 p.
Notes:	Source: Masters Abstracts International, Volume: 55-02.
Contained By:	Masters Abstracts International55-02(E).
Subject:	Biology.
Subject:	Immunology.
ISBN:	9781339163581
[NT 15000229]:	The key objective of vaccination is the induction of an effective pathogen-specific immune response that leads to protection against infection and/or disease caused by that pathogen. New vaccine technologies have resulted in second-generation recombinant vaccines containing highly purified antigens with improved tolerability and safety profiles. Unfortunately, the immune responses they induce are suboptimal without the help of adjuvants. This project investigates the bacterial carrier molecule from Clostridium thermocellum a modified Lichenase (LicKM), to determine if it posses adjuvant-like capabilities. This thermostable enzyme contains a catalytic domain loop structure separating it into two regions; an N-terminal and C-terminal region (Musiychuk, 2007). Target protein sequences are expressed as either N or C terminal fusions; LicKM may contain a single or double fusions (Musiychuk, 2007). We hypothesize, based upon preliminary results that this molecule serves a dual purpose, as a carrier of dominant epitopes for presentation to antigen presenting cells during vaccination and also as an adjuvant enhancing immunity. Here, we investigated expression of common dendritic cell (DC) markers in the presence of LicKM. Next, the ability of LicKM to suppress the immune response in the presence of a potent activator was assessed. To start to elucidate the potential mechanism of action of LicKM, the interaction of host immune cells with the carrier protein was analyzed. Finally, the humoral immune response following vaccination with LicKM fused target antigens was analyzed. The ultimate goal of this proposal is to demonstrate if LicKM possesses novel adjuvant properties responsible for the development of enhanced cell-mediated responses.
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1602338

Utilization of a model vaccination system to evaluate the immunostimulatory characteristics of LicKM, a novel carrier molecule.
Chabot, Ashley Lynn.

Utilization of a model vaccination system to evaluate the immunostimulatory characteristics of LicKM, a novel carrier molecule. - 95 p.

Source: Masters Abstracts International, Volume: 55-02.

Thesis (M.S.)--University of Delaware, 2015.

The key objective of vaccination is the induction of an effective pathogen-specific immune response that leads to protection against infection and/or disease caused by that pathogen. New vaccine technologies have resulted in second-generation recombinant vaccines containing highly purified antigens with improved tolerability and safety profiles. Unfortunately, the immune responses they induce are suboptimal without the help of adjuvants. This project investigates the bacterial carrier molecule from Clostridium thermocellum a modified Lichenase (LicKM), to determine if it posses adjuvant-like capabilities. This thermostable enzyme contains a catalytic domain loop structure separating it into two regions; an N-terminal and C-terminal region (Musiychuk, 2007). Target protein sequences are expressed as either N or C terminal fusions; LicKM may contain a single or double fusions (Musiychuk, 2007). We hypothesize, based upon preliminary results that this molecule serves a dual purpose, as a carrier of dominant epitopes for presentation to antigen presenting cells during vaccination and also as an adjuvant enhancing immunity. Here, we investigated expression of common dendritic cell (DC) markers in the presence of LicKM. Next, the ability of LicKM to suppress the immune response in the presence of a potent activator was assessed. To start to elucidate the potential mechanism of action of LicKM, the interaction of host immune cells with the carrier protein was analyzed. Finally, the humoral immune response following vaccination with LicKM fused target antigens was analyzed. The ultimate goal of this proposal is to demonstrate if LicKM possesses novel adjuvant properties responsible for the development of enhanced cell-mediated responses.

ISBN: 9781339163581Subjects--Topical Terms:

171887
Biology.

Utilization of a model vaccination system to evaluate the immunostimulatory characteristics of LicKM, a novel carrier molecule.
LDR:02657nam a2200277 4500 001 440941
005 20160422125034.5
008 160525s2015 ||||||||||||||||| ||eng d
020 $a 9781339163581
035 $a (MiAaPQ)AAI1602338
035 $a AAI1602338
040 $a MiAaPQ $c MiAaPQ
100 1 $a Chabot, Ashley Lynn. $3 629948
245 1 0 $a Utilization of a model vaccination system to evaluate the immunostimulatory characteristics of LicKM, a novel carrier molecule.
300 $a 95 p.
500 $a Source: Masters Abstracts International, Volume: 55-02.
500 $a Adviser: Michelle Parent.
502 $a Thesis (M.S.)--University of Delaware, 2015.
520 $a The key objective of vaccination is the induction of an effective pathogen-specific immune response that leads to protection against infection and/or disease caused by that pathogen. New vaccine technologies have resulted in second-generation recombinant vaccines containing highly purified antigens with improved tolerability and safety profiles. Unfortunately, the immune responses they induce are suboptimal without the help of adjuvants. This project investigates the bacterial carrier molecule from Clostridium thermocellum a modified Lichenase (LicKM), to determine if it posses adjuvant-like capabilities. This thermostable enzyme contains a catalytic domain loop structure separating it into two regions; an N-terminal and C-terminal region (Musiychuk, 2007). Target protein sequences are expressed as either N or C terminal fusions; LicKM may contain a single or double fusions (Musiychuk, 2007). We hypothesize, based upon preliminary results that this molecule serves a dual purpose, as a carrier of dominant epitopes for presentation to antigen presenting cells during vaccination and also as an adjuvant enhancing immunity. Here, we investigated expression of common dendritic cell (DC) markers in the presence of LicKM. Next, the ability of LicKM to suppress the immune response in the presence of a potent activator was assessed. To start to elucidate the potential mechanism of action of LicKM, the interaction of host immune cells with the carrier protein was analyzed. Finally, the humoral immune response following vaccination with LicKM fused target antigens was analyzed. The ultimate goal of this proposal is to demonstrate if LicKM possesses novel adjuvant properties responsible for the development of enhanced cell-mediated responses.
590 $a School code: 0060.
650 4 $a Biology. $3 171887
650 4 $a Immunology. $3 402223
690 $a 0306
690 $a 0982
710 2 $a University of Delaware. $b Department of Biological Sciences. $3 629949
773 0 $t Masters Abstracts International $g 55-02(E).
790 $a 0060
791 $a M.S.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1602338